Objectives: To analyse serogroup (Sg)- and finetype-specific invasive meningococcal disease burden (IMD) in Germany, 2002–2010, with emphasis on effects of vaccination with conjugate SgC vaccines targeting one-year old children since 2006, including individual-based catch-up to 17 years of age. Methods: Serogroup- and age-specific IMD incidence and trends were calculated using statutory surveillance data. The national reference laboratory performed genetic finetyping. Vaccination uptake data were obtained from school entry surveys and prescription monitoring. Results: In person
Scholz S, Schwarz M, Beck E, et al. Public Health Impact and Cost-Effectiveness Analysis of Routine ...
Background: The total incidence of invasive meningococcal disease (IMD) in Europe has been declinin...
The incidence of invasive meningococcal disease (IMD) in Italy is among the lowest in Europe. Mening...
Objectives: To analyse serogroup (Sg)- and finetype-specific invasive meningococcal disease burde...
Invasive meningococcal disease (IMD) is a major cause of bacterial meningitis and septicaemia althou...
In December 2013 Bexsero® became available in Germany for vaccination against serogroup B meningococ...
International audienceBackground: Invasive meningococcal disease (IMD) is a major cause of bacterial...
Gruhn S, Witte J, Greiner W, et al. Epidemiology and economic burden of meningococcal disease in Ger...
Neisseria meningitidis is a major cause of bacterial meningitis and septicaemia worldwide and is ass...
BACKGROUND: Epidemiological data for invasive meningococcal disease is essential for public health p...
Notwithstanding different meningococcal serogroups have changed their distribution and their impact ...
AbstractInvasive meningococcal disease (IMD) caused by Neisseria meningitidis is associated with hig...
International audienceOBJECTIVES:This work aimed to describe the epidemiology of invasive meningococ...
In Italy, the meningococcal C conjugate vaccine (MenC) has been offered in most regions since 2009-2...
OBJECTIVES: In 2015 the UK became the first country to implement the meningococcal B (MenB) vaccine,...
Scholz S, Schwarz M, Beck E, et al. Public Health Impact and Cost-Effectiveness Analysis of Routine ...
Background: The total incidence of invasive meningococcal disease (IMD) in Europe has been declinin...
The incidence of invasive meningococcal disease (IMD) in Italy is among the lowest in Europe. Mening...
Objectives: To analyse serogroup (Sg)- and finetype-specific invasive meningococcal disease burde...
Invasive meningococcal disease (IMD) is a major cause of bacterial meningitis and septicaemia althou...
In December 2013 Bexsero® became available in Germany for vaccination against serogroup B meningococ...
International audienceBackground: Invasive meningococcal disease (IMD) is a major cause of bacterial...
Gruhn S, Witte J, Greiner W, et al. Epidemiology and economic burden of meningococcal disease in Ger...
Neisseria meningitidis is a major cause of bacterial meningitis and septicaemia worldwide and is ass...
BACKGROUND: Epidemiological data for invasive meningococcal disease is essential for public health p...
Notwithstanding different meningococcal serogroups have changed their distribution and their impact ...
AbstractInvasive meningococcal disease (IMD) caused by Neisseria meningitidis is associated with hig...
International audienceOBJECTIVES:This work aimed to describe the epidemiology of invasive meningococ...
In Italy, the meningococcal C conjugate vaccine (MenC) has been offered in most regions since 2009-2...
OBJECTIVES: In 2015 the UK became the first country to implement the meningococcal B (MenB) vaccine,...
Scholz S, Schwarz M, Beck E, et al. Public Health Impact and Cost-Effectiveness Analysis of Routine ...
Background: The total incidence of invasive meningococcal disease (IMD) in Europe has been declinin...
The incidence of invasive meningococcal disease (IMD) in Italy is among the lowest in Europe. Mening...